 Enrique Alvarez
Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 35 | 2024 | 384 | 8.860 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 11 | 2024 | 68 | 2.770 |
Why?
| | Immunologic Factors | 7 | 2020 | 225 | 2.700 |
Why?
| | Fingolimod Hydrochloride | 6 | 2020 | 32 | 2.550 |
Why?
| | Natalizumab | 5 | 2023 | 46 | 2.450 |
Why?
| | Multiple Sclerosis, Chronic Progressive | 6 | 2023 | 25 | 2.370 |
Why?
| | Rituximab | 6 | 2023 | 155 | 1.940 |
Why?
| | Immunosuppressive Agents | 9 | 2024 | 681 | 1.540 |
Why?
| | Dimethyl Fumarate | 3 | 2020 | 10 | 1.110 |
Why?
| | Agammaglobulinemia | 2 | 2023 | 32 | 1.110 |
Why?
| | Neuromyelitis Optica | 4 | 2020 | 112 | 0.820 |
Why?
| | Serum Sickness | 1 | 2019 | 7 | 0.720 |
Why?
| | Pregnancy Complications | 2 | 2018 | 448 | 0.580 |
Why?
| | Medical Marijuana | 1 | 2018 | 102 | 0.580 |
Why?
| | Lymphocyte Depletion | 3 | 2021 | 119 | 0.560 |
Why?
| | Axons | 2 | 2014 | 185 | 0.540 |
Why?
| | Marijuana Smoking | 1 | 2018 | 220 | 0.520 |
Why?
| | Antibodies, Monoclonal, Humanized | 5 | 2023 | 667 | 0.520 |
Why?
| | Oligoclonal Bands | 1 | 2014 | 20 | 0.510 |
Why?
| | Neurofilament Proteins | 1 | 2014 | 33 | 0.510 |
Why?
| | Biomarkers | 3 | 2023 | 3588 | 0.490 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 969 | 0.470 |
Why?
| | Anemia | 1 | 2015 | 146 | 0.470 |
Why?
| | Chemokine CXCL13 | 1 | 2013 | 7 | 0.460 |
Why?
| | Recurrence | 6 | 2024 | 975 | 0.450 |
Why?
| | Humans | 51 | 2024 | 118974 | 0.440 |
Why?
| | Adult | 24 | 2023 | 31512 | 0.430 |
Why?
| | Antibodies, Monoclonal | 4 | 2022 | 1284 | 0.400 |
Why?
| | Middle Aged | 23 | 2024 | 27617 | 0.390 |
Why?
| | T-Lymphocytes | 3 | 2023 | 1774 | 0.360 |
Why?
| | Female | 29 | 2024 | 61565 | 0.360 |
Why?
| | Magnetic Resonance Imaging | 8 | 2022 | 3174 | 0.340 |
Why?
| | Brain | 7 | 2021 | 2490 | 0.340 |
Why?
| | Walking | 4 | 2023 | 415 | 0.340 |
Why?
| | Glatiramer Acetate | 2 | 2019 | 20 | 0.320 |
Why?
| | Antigens, CD20 | 2 | 2023 | 28 | 0.280 |
Why?
| | B-Lymphocytes | 3 | 2023 | 770 | 0.280 |
Why?
| | Male | 23 | 2024 | 57801 | 0.270 |
Why?
| | Chromosomes, Human, X | 1 | 2005 | 58 | 0.270 |
Why?
| | Multigene Family | 1 | 2005 | 200 | 0.250 |
Why?
| | Demyelinating Diseases | 2 | 2022 | 79 | 0.250 |
Why?
| | Retrospective Studies | 8 | 2023 | 12978 | 0.240 |
Why?
| | Atrophy | 2 | 2021 | 164 | 0.230 |
Why?
| | Diphosphonates | 1 | 2003 | 50 | 0.230 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2003 | 63 | 0.230 |
Why?
| | Neuroprotection | 1 | 2023 | 31 | 0.230 |
Why?
| | Fatigue | 2 | 2024 | 297 | 0.230 |
Why?
| | Alemtuzumab | 1 | 2023 | 12 | 0.230 |
Why?
| | Bone Resorption | 1 | 2003 | 80 | 0.230 |
Why?
| | Quality of Life | 4 | 2023 | 2366 | 0.210 |
Why?
| | Neuroblastoma | 1 | 2023 | 135 | 0.210 |
Why?
| | Gadolinium | 2 | 2022 | 79 | 0.210 |
Why?
| | Drug Costs | 1 | 2023 | 94 | 0.210 |
Why?
| | Inflammation | 1 | 2013 | 2566 | 0.210 |
Why?
| | Interoception | 1 | 2021 | 2 | 0.210 |
Why?
| | Diagnostic Self Evaluation | 1 | 2021 | 25 | 0.200 |
Why?
| | Resistance Training | 1 | 2024 | 120 | 0.200 |
Why?
| | Stair Climbing | 1 | 2021 | 2 | 0.200 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 551 | 0.200 |
Why?
| | Killer Cells, Natural | 2 | 2021 | 381 | 0.200 |
Why?
| | Lymphopenia | 1 | 2020 | 48 | 0.190 |
Why?
| | Treatment Outcome | 6 | 2021 | 9342 | 0.190 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 112 | 0.190 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2005 | 814 | 0.180 |
Why?
| | Personality | 1 | 2021 | 115 | 0.180 |
Why?
| | Cancer Vaccines | 1 | 2021 | 139 | 0.180 |
Why?
| | Interferon-gamma | 1 | 2023 | 736 | 0.180 |
Why?
| | Neutropenia | 1 | 2020 | 133 | 0.180 |
Why?
| | Muscle Strength | 2 | 2024 | 283 | 0.180 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2019 | 18 | 0.180 |
Why?
| | Disease Management | 1 | 2023 | 571 | 0.170 |
Why?
| | Immunotherapy, Adoptive | 1 | 2021 | 191 | 0.170 |
Why?
| | Young Adult | 5 | 2021 | 10793 | 0.170 |
Why?
| | Double-Blind Method | 5 | 2022 | 1687 | 0.170 |
Why?
| | Nerve Net | 1 | 2021 | 232 | 0.170 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2018 | 86 | 0.160 |
Why?
| | Muscle Spasticity | 1 | 2018 | 53 | 0.160 |
Why?
| | Dendritic Cells | 1 | 2021 | 442 | 0.160 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 245 | 0.150 |
Why?
| | Postural Balance | 1 | 2019 | 184 | 0.150 |
Why?
| | Psychomotor Performance | 1 | 2019 | 290 | 0.150 |
Why?
| | Interferon beta-1a | 1 | 2016 | 12 | 0.150 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4596 | 0.150 |
Why?
| | Disease Progression | 5 | 2022 | 2490 | 0.150 |
Why?
| | Electric Stimulation Therapy | 1 | 2018 | 74 | 0.150 |
Why?
| | T-Lymphocyte Subsets | 1 | 2019 | 396 | 0.140 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2023 | 827 | 0.140 |
Why?
| | Transcription Factor RelA | 1 | 2016 | 82 | 0.140 |
Why?
| | Lymphocyte Activation | 2 | 2019 | 1067 | 0.140 |
Why?
| | Mycophenolic Acid | 1 | 2016 | 79 | 0.140 |
Why?
| | CD40 Antigens | 1 | 2016 | 80 | 0.140 |
Why?
| | Drug Administration Schedule | 1 | 2018 | 736 | 0.140 |
Why?
| | Contrast Media | 1 | 2018 | 373 | 0.130 |
Why?
| | Postpartum Period | 1 | 2017 | 271 | 0.130 |
Why?
| | Physicians | 1 | 2023 | 794 | 0.130 |
Why?
| | Pyridines | 1 | 2018 | 440 | 0.130 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 292 | 0.130 |
Why?
| | Neurons | 3 | 2011 | 1345 | 0.130 |
Why?
| | Survival Analysis | 1 | 2018 | 1267 | 0.130 |
Why?
| | Melanoma | 1 | 2021 | 664 | 0.120 |
Why?
| | Disability Evaluation | 4 | 2018 | 280 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2021 | 762 | 0.120 |
Why?
| | Pain, Intractable | 1 | 2012 | 8 | 0.110 |
Why?
| | Muscle, Skeletal | 4 | 2024 | 1515 | 0.110 |
Why?
| | Pain | 1 | 2018 | 735 | 0.110 |
Why?
| | Dopamine | 2 | 2005 | 249 | 0.100 |
Why?
| | Time Factors | 2 | 2021 | 6412 | 0.100 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2011 | 39 | 0.100 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 82 | 0.100 |
Why?
| | Infusions, Intravenous | 2 | 2023 | 380 | 0.100 |
Why?
| | Antigen-Presenting Cells | 1 | 2011 | 156 | 0.100 |
Why?
| | Adolescent | 4 | 2021 | 18480 | 0.090 |
Why?
| | Movement | 2 | 2023 | 248 | 0.090 |
Why?
| | Leukocytes | 1 | 2011 | 290 | 0.090 |
Why?
| | Pregnancy | 2 | 2018 | 5691 | 0.090 |
Why?
| | Lymphocytes | 1 | 2011 | 347 | 0.090 |
Why?
| | Immunoglobulin G | 2 | 2023 | 788 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2013 | 3171 | 0.080 |
Why?
| | Spinal Cord | 2 | 2012 | 367 | 0.080 |
Why?
| | Aged | 4 | 2019 | 19657 | 0.080 |
Why?
| | MicroRNAs | 1 | 2013 | 637 | 0.070 |
Why?
| | Pilot Projects | 2 | 2021 | 1419 | 0.070 |
Why?
| | Rats | 2 | 2005 | 5392 | 0.070 |
Why?
| | Immunologic Memory | 2 | 2019 | 313 | 0.070 |
Why?
| | Haplorhini | 1 | 2005 | 62 | 0.070 |
Why?
| | Sequence Homology, Nucleic Acid | 1 | 2005 | 155 | 0.070 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2005 | 139 | 0.060 |
Why?
| | Risk Factors | 1 | 2018 | 9000 | 0.060 |
Why?
| | Organ Specificity | 1 | 2005 | 278 | 0.060 |
Why?
| | Cytoplasm | 1 | 2005 | 269 | 0.060 |
Why?
| | Animals | 4 | 2023 | 33381 | 0.060 |
Why?
| | Species Specificity | 1 | 2005 | 565 | 0.060 |
Why?
| | Parathyroid Hormone-Related Protein | 1 | 2003 | 21 | 0.060 |
Why?
| | Tyrosine 3-Monooxygenase | 1 | 2004 | 70 | 0.060 |
Why?
| | Osteolysis | 1 | 2003 | 12 | 0.060 |
Why?
| | Nerve Growth Factors | 1 | 2004 | 74 | 0.060 |
Why?
| | Models, Biological | 1 | 2011 | 1715 | 0.060 |
Why?
| | Rats, Inbred F344 | 1 | 2003 | 245 | 0.060 |
Why?
| | Pluripotent Stem Cells | 1 | 2004 | 65 | 0.060 |
Why?
| | Cytokines | 1 | 2011 | 1900 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2005 | 770 | 0.060 |
Why?
| | Crotonates | 1 | 2022 | 3 | 0.060 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 2022 | 3 | 0.060 |
Why?
| | Toluidines | 1 | 2022 | 5 | 0.060 |
Why?
| | Hydroxybutyrates | 1 | 2022 | 11 | 0.060 |
Why?
| | Arthritis, Rheumatoid | 1 | 2011 | 989 | 0.050 |
Why?
| | Cell Nucleus | 1 | 2005 | 580 | 0.050 |
Why?
| | Arm | 1 | 2023 | 106 | 0.050 |
Why?
| | Intermediate Filaments | 1 | 2022 | 46 | 0.050 |
Why?
| | Regional Blood Flow | 1 | 2024 | 418 | 0.050 |
Why?
| | Patient Outcome Assessment | 1 | 2023 | 122 | 0.050 |
Why?
| | Nitriles | 1 | 2022 | 155 | 0.050 |
Why?
| | Cell Division | 1 | 2003 | 776 | 0.050 |
Why?
| | Gray Matter | 1 | 2022 | 66 | 0.050 |
Why?
| | MART-1 Antigen | 1 | 2021 | 9 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 253 | 0.050 |
Why?
| | Injections, Subcutaneous | 1 | 2021 | 138 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 544 | 0.050 |
Why?
| | Heart | 1 | 2005 | 631 | 0.050 |
Why?
| | Base Sequence | 1 | 2005 | 2159 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2024 | 749 | 0.050 |
Why?
| | Research Report | 1 | 2021 | 75 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2003 | 462 | 0.050 |
Why?
| | Electric Stimulation | 1 | 2021 | 268 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2005 | 2871 | 0.050 |
Why?
| | Cell Survival | 1 | 2003 | 1047 | 0.050 |
Why?
| | Neuroimaging | 1 | 2022 | 256 | 0.050 |
Why?
| | Complement System Proteins | 1 | 2023 | 294 | 0.050 |
Why?
| | Mobility Limitation | 1 | 2020 | 62 | 0.050 |
Why?
| | Antibodies, Viral | 1 | 2023 | 542 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 304 | 0.040 |
Why?
| | Drug Substitution | 1 | 2019 | 46 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2019 | 23 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2019 | 136 | 0.040 |
Why?
| | Adaptation, Physiological | 1 | 2023 | 502 | 0.040 |
Why?
| | Motor Skills | 1 | 2019 | 85 | 0.040 |
Why?
| | Induction Chemotherapy | 1 | 2019 | 59 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1597 | 0.040 |
Why?
| | Hand | 1 | 2019 | 137 | 0.040 |
Why?
| | Diffusion Tensor Imaging | 1 | 2018 | 73 | 0.040 |
Why?
| | Biomechanical Phenomena | 1 | 2021 | 683 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2019 | 128 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 1166 | 0.040 |
Why?
| | Knee Joint | 1 | 2021 | 353 | 0.040 |
Why?
| | Homeostasis | 1 | 2021 | 594 | 0.040 |
Why?
| | Leg | 1 | 2019 | 234 | 0.040 |
Why?
| | Mice | 2 | 2023 | 15520 | 0.040 |
Why?
| | Headache | 1 | 2018 | 128 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1223 | 0.040 |
Why?
| | Organ Size | 1 | 2018 | 460 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 4552 | 0.040 |
Why?
| | Liver | 1 | 2005 | 1816 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1244 | 0.040 |
Why?
| | Internet | 1 | 2021 | 633 | 0.040 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 187 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2003 | 2851 | 0.040 |
Why?
| | Cell Differentiation | 1 | 2004 | 1753 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2019 | 359 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 160 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 5116 | 0.030 |
Why?
| | Risk | 1 | 2017 | 853 | 0.030 |
Why?
| | Prognosis | 1 | 2022 | 3443 | 0.030 |
Why?
| | Incidence | 1 | 2020 | 2424 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 965 | 0.030 |
Why?
| | Apoptosis | 1 | 2023 | 2484 | 0.030 |
Why?
| | Genetic Markers | 1 | 2013 | 348 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2003 | 1974 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1355 | 0.030 |
Why?
| | Prospective Studies | 1 | 2024 | 6471 | 0.030 |
Why?
| | Phosphorylation | 1 | 2016 | 1633 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2023 | 5255 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2012 | 403 | 0.030 |
Why?
| | Down-Regulation | 1 | 2013 | 627 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 829 | 0.020 |
Why?
| | Pain Measurement | 1 | 2012 | 469 | 0.020 |
Why?
| | Depression | 1 | 2018 | 1132 | 0.020 |
Why?
| | Pain Management | 1 | 2012 | 294 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1868 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2017 | 6561 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2674 | 0.020 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2004 | 17 | 0.020 |
Why?
| | Mesencephalon | 1 | 2004 | 57 | 0.010 |
Why?
| | Cell Shape | 1 | 2004 | 57 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2004 | 112 | 0.010 |
Why?
| | Stromal Cells | 1 | 2004 | 102 | 0.010 |
Why?
| | Coculture Techniques | 1 | 2004 | 208 | 0.010 |
Why?
| | Stem Cell Transplantation | 1 | 2004 | 153 | 0.010 |
Why?
| | Corpus Striatum | 1 | 2004 | 127 | 0.010 |
Why?
| | Astrocytes | 1 | 2004 | 177 | 0.010 |
Why?
| | United States | 1 | 2018 | 12555 | 0.010 |
Why?
| | Parkinson Disease | 1 | 2004 | 334 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2004 | 2275 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4077 | 0.010 |
Why?
| | Phenotype | 1 | 2004 | 3003 | 0.010 |
Why?
|
|
Alvarez's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|